VKTX
NASDAQViking Therapeutics Inc.
Price$32.81-1.29 (-3.78%)
01:45 PM07:45 PM
News · 26 weeks440%
2025-10-262026-04-19
Mix1690d
- Earnings4(25%)
- SEC Filings4(25%)
- Other4(25%)
- Insider3(19%)
- Analyst1(6%)
Latest news
25 items- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- PRViking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, April 10, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will attend multiple upcoming investor conferences. Details of the company's participation are as follows:Raymond James Biotech/BioPharma Conference 2026Details: Viking management will participate in 1-on-1 meetingsConference Date: April 14, 2026Location: New York, NYPiper Sandler Spring Biopharma Symposium 2026Details: Viking
- SECSEC Form DEFA14A filed by Viking Therapeutics Inc.DEFA14A - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECSEC Form DEF 14A filed by Viking Therapeutics Inc.DEF 14A - Viking Therapeutics, Inc. (0001607678) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
- ANALYSTWolfe Research initiated coverage on Viking TherapeuticsWolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform
- PRViking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK273578-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 DiabetesSAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.
- INSIDERSEC Form 4 filed by Viking Therapeutics Inc.4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- PRViking Therapeutics to Participate at Upcoming Investor ConferencesSAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences. Details of the company's participation are as follows:Leerink Partners Global Healthcare Conference 2026Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 8-11, 2026Fireside Chat Timing: 10:40 – 11:10 a.m. Eastern
- SECSEC Form 10-K filed by Viking Therapeutics Inc.10-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate UpdateConference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended
- SECViking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
- PRViking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2025 after the market close on Wednesday, February 11, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m.
- INSIDERSEC Form 4 filed by Chief Commercial Officer Aubuchon Neil William4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERSEC Form 3 filed by new insider Aubuchon Neil William3 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- PRViking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPublication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of the results of the company's Phase 2 VENTURE clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and
- PRViking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in ObesityStudy is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for
- PRViking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial OfficerExperienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Neil Aubuchon as chief commercial officer. Mr. Aubuchon brings more than two decades of biopharmaceutical industry experience spanning leadership roles across global commercial and marketing functions including focus within the cardiometabolic space.
- INSIDERChief Financial Officer Zante Greg was granted 73,049 shares and sold $1,896,969 worth of shares (57,661 units at $32.90), increasing direct ownership by 9% to 189,891 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERChief Operating Officer Mancini Marianna was granted 73,049 shares and sold $1,901,405 worth of shares (57,661 units at $32.98), increasing direct ownership by 4% to 409,190 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERPresident & CEO Lian Brian sold $7,692,121 worth of shares (233,409 units at $32.96) and was granted 302,480 shares, increasing direct ownership by 3% to 2,499,291 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERDirector Singleton J Matthew was granted 3,150 shares, increasing direct ownership by 33% to 12,650 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERDirector Macartney Lawson was granted 3,150 shares, increasing direct ownership by 7% to 51,115 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
- INSIDERDirector Rowland Charles A Jr was granted 3,150 shares, increasing direct ownership by 10% to 33,150 units (SEC Form 4)4 - Viking Therapeutics, Inc. (0001607678) (Issuer)